Lifeline Scientific, Inc Strategic review update (2652C)
27 6월 2016 - 3:00PM
UK Regulatory
TIDMLSIC
RNS Number : 2652C
Lifeline Scientific, Inc
27 June 2016
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
Strategic review update
Lifeline Scientific (AIM: LSIC), the transplantation technology
company, provides the following update regarding its strategic
review as last discussed in its preliminary results announcement of
29 April, 2016. While the final outcome of its strategic review has
not yet been reached, the Board can confirm that discussions
continue with interested parties. These discussions may or may not
lead to an offer for the Company and no assurances can be made as
to the outcome of these discussions. The Board intends to update
the market upon its decision regarding the outcome of the strategic
review in due course.
The prospects for Lifeline Scientific remain solid for 2016,
with trading-to date significantly ahead of the same period last
year. Lifeline will provide a trading update on first half results
during August 2016.
For further information:
Lifeline Scientific, www.lifeline-scientific.com
Inc.
David Kravitz, CEO Tel: +1 847 294 0300
Lisa Kieres, CFO Tel: +1 847 294 0300
Panmure Gordon (UK) Tel: +44 (0)20 7886 2500
Limited
Freddy Crossley (Corporate
Finance)
Tom Salvesen (Corporate
Broking)
Walbrook PR Limited Tel: +44 (0) 20 7933 8780 or
lifeline@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Lianne Cawthorne Mob: +44 (0)7584 391 303
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product, LifePort Kidney Transporter, is
the global market-leading medical device for hypothermic machine
preservation of donor kidneys. LifePorts and novel solutions
designed for preservation of other organs are in development, with
LifePort Liver Transporter next in line for commercial launch. For
more information please visit www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to help improve kidney preservation, evaluation and
transport prior to transplantation. It has been widely studied in
clinical trials throughout the world and is the standard of care
for machine preservation of donor kidneys. Employed by surgeons in
over 218 leading transplant programmes in 32 countries, LifePorts
have successfully preserved more than 70,000 kidneys indicated for
clinical transplant. For more information please visit
www.organ-recovery.com
About LifePort Liver Transporter
LifePort Liver Transporter is modelled upon the clinically
proven technology platform of LifePort Kidney Transporter and the
Company's early HMP prototype successfully used in clinical
transplant studies by surgeons at New York-Presbyterian
Hospital/Columbia University Medical Center. LifePort Liver
Transporter and the Company's proprietary machine preservation
solution, Vasosol(R), are in the process of US and international
regulatory registrations. The system is designed to help improve
outcomes in liver transplantation by enabling the clinical use of
hypothermic machine perfusion, and has been developed in
consultation with clinical and research teams specialising in liver
transplantation at Columbia University Medical Center and the
University of Chicago. The system employs a rugged, streamlined
ergonomic design for ease of use and transportability from donor
bedside to recipient operating room. For more information please
visit: http://www.organ-recovery.com/pipeline.php
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCAKQDNPBKDOAB
(END) Dow Jones Newswires
June 27, 2016 02:00 ET (06:00 GMT)
Lifeline Sci (LSE:LSIC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Lifeline Sci (LSE:LSIC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024